212 related articles for article (PubMed ID: 10575998)
41. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial.
Lufkin EG; Sarkar S; Kulkarni PM; Ciaccia AV; Siddhanti S; Stock J; Plouffe L
Curr Med Res Opin; 2004 Mar; 20(3):351-7. PubMed ID: 15025844
[TBL] [Abstract][Full Text] [Related]
42. Initiation of osteoporosis treatment after bone mineral density testing.
Pressman A; Forsyth B; Ettinger B; Tosteson AN
Osteoporos Int; 2001; 12(5):337-42. PubMed ID: 11444079
[TBL] [Abstract][Full Text] [Related]
43. Osteoporosis prevention and therapy: preserving and building strength through bone quality.
Kleerekoper M
Osteoporos Int; 2006 Dec; 17(12):1707-15. PubMed ID: 16909196
[TBL] [Abstract][Full Text] [Related]
44. [Molecular mechanism tissue-specific actions of selective estrogen receptor modulators].
Urano T
Nihon Ronen Igakkai Zasshi; 2006 Mar; 43(2):147-51. PubMed ID: 16683636
[No Abstract] [Full Text] [Related]
45. Pharmacologic therapy for the treatment and prevention of osteoporosis.
McClung B; McClung M
Nurs Clin North Am; 2001 Sep; 36(3):433-40, viii. PubMed ID: 11532658
[TBL] [Abstract][Full Text] [Related]
46. Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis?
Papadokostakis G; Katonis P; Damilakis J; Hadjipavlou A
Eur Spine J; 2005 Dec; 14(10):977-81. PubMed ID: 15834592
[TBL] [Abstract][Full Text] [Related]
47. Raloxifene: a new choice for treating and preventing osteoporosis.
Licata AA; Ciaccia AV; Wong M; Draper MW
Cleve Clin J Med; 2000 Apr; 67(4):273-80. PubMed ID: 10780099
[TBL] [Abstract][Full Text] [Related]
48. [Therapeutic strategies for osteoporosis].
Chapurlat R; Delmas PD
Ann Med Interne (Paris); 2000 Oct; 151(6):471-6. PubMed ID: 11104926
[TBL] [Abstract][Full Text] [Related]
49. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
[TBL] [Abstract][Full Text] [Related]
50. Vertebroplasty: an opportunity to do something really good for patients.
Einhorn TA
Spine (Phila Pa 1976); 2000 May; 25(9):1051-2. PubMed ID: 10788846
[No Abstract] [Full Text] [Related]
51. [Osteoporosis].
Treatment recommending task force group
Duodecim; 2000; 116(16):1772-88. PubMed ID: 12001456
[No Abstract] [Full Text] [Related]
52. [Raloxifene - an unexploited possibility of prevention and treatment of postmenopausal osteoporosis].
Štěpán J; Rosa J; Pavelka K
Vnitr Lek; 2016; 62(10):781-788. PubMed ID: 27900864
[TBL] [Abstract][Full Text] [Related]
53. How does raloxifene reduce fracture risk?
McClung MR
Menopause; 2002; 9(5):306-8. PubMed ID: 12218718
[No Abstract] [Full Text] [Related]
54. Therapy for osteoporosis.
Gray K
J S C Med Assoc; 2001 Mar; 97(3):114-6. PubMed ID: 11285883
[No Abstract] [Full Text] [Related]
55. The effects of selective estrogen receptor modulator treatment following hormone replacement therapy on elderly postmenopausal women with osteoporosis.
Hayashi T; Ina K; Maeda M; Nomura H
Nitric Oxide; 2011 May; 24(4):199-203. PubMed ID: 21513812
[TBL] [Abstract][Full Text] [Related]
56. Pharmacologic prevention of osteoporotic fractures.
Zizic TM
Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
[TBL] [Abstract][Full Text] [Related]
57. Raloxifene and risk of vertebral fracture in postmenopausal women.
Halbekath J; Becker-Brüser W; Wille H
JAMA; 2000 May; 283(17):2236-7. PubMed ID: 10807376
[No Abstract] [Full Text] [Related]
58. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
59. Case of the month. Osteoporosis in a postmenopausal woman.
Chaudhry MU
J Ark Med Soc; 2002 Jan; 98(7):232-4. PubMed ID: 11778301
[No Abstract] [Full Text] [Related]
60. [Optimal osteoporosis strategy?].
Scharla S; Reichenhall B
Krankenpfl J; 2005; 43(1-3):65. PubMed ID: 15912853
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
